FierceBiotechOriginal article
{"a":[{"_":"Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent","$":{"href":"/biotech/attovia-files-ipo-take-sanofi-and-regenerons-dupixent","hreflang":"en"}}]}
IPO/OfferingDupixentNemluvioAttovia drug candidatePositive
AI Analysis
Summary
Attovia Therapeutics has filed for an IPO to fund development of a drug candidate designed to compete with Sanofi/Regeneron's Dupixent and Galderma's Nemluvio.
Importance:6/10
Sentiment:
0.40
IPOAttoviafundraisingDupixent competitordermatology
Read the original article
Published by FierceBiotech on July 15, 2026 4:09 AM